bearish
Shanghai Henlius (复宏汉霖) IPO: Not an Impressive Biosimilar Portfolio
1.1k Views30 Jan 2019 10:22
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In this insight, we will discuss the following topics:
The...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
- ECM Weekly (23 February 2019) - Futu, CStone, Dexin, New Century, AB InBev, MabPharma23 Feb 2019
- MabPharma (迈博医药) IPO: Assembled for a Trade?21 Feb 2019
- HLX02: Innovation Could Overtake19 Feb 2019
- Shanghai Henlius (复宏汉霖) IPO: Not an Impressive Biosimilar Portfolio30 Jan 2019
- CStone Pharma (基石药业) IPO: Strong Assembly and Backing (Part 1)25 Jan 2019
- Innovent Biologics IPO Valuation: Surprisingly Grounded in Reality15 Oct 2018
x